Susquehanna initiated coverage on Endo Pharmaceuticals (Nasdaq: ENDP) with a Neutral rating and $36 price target.
This article: 78 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE